Lamkap Bio Alpha AG's κλ bispecific antibodies include a κ light chain recognizing one target and a λ light chain recognizing a second target. The company has presented data showing the benefit of combining a bispecific antibody targeting CEA (CEACAM5) on tumor cells and CD3 on T cells, NILK-2301, and a bispecific antibody targeting CEA on tumor cells and CD28 on T cells, NILK-3301.
Polycomb repressive complex 2 (PRC2) is composed of several subunits, such as EZH2, EED and SUZ12, and is a regulator of cell proliferation and development. Targeting the allosteric subunit EED may be a new approach for fully inhibiting PRC2 complex activity and addressing the limitations of EZH2 inhibition.
Immune checkpoint inhibitors are useful for the treatment of solid tumors, but in many tumors, only partial response is achieved. The antitumoral efficacy of Enlivex Therapeutics Ltd.'s Allocetra-OTS, a cellular therapy, was investigated in animal models of solid tumors.
Medshine Discovery Inc. has described gonadotropin-releasing hormone receptor (GnRHR) antagonists reported to be useful for the treatment of prostate cancer.
Researchers from Janssen Pharmaceutica NV reported the discovery of novel potent fluoroallylamide induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors for the treatment of hematologic malignancies.
GPC3 is an oncofetal antigen highly expressed in hepatocellular carcinoma (HCC) but minimally expressed in adult normal tissues, except the placenta. Cytovia Therapeutics Inc. has presented preclinical data on CYT-303, a bispecific natural killer (NK) engager targeting NK cell-activating receptor NKp46 and GPC3 expressed in tumor cells.
Epidermal growth factor receptor (EGFR) is a target in many cancers, but EGFR inhibitors have displayed little utility in treating glioblastoma (GBM) due to limited blood-brain barrier (BBB) penetration.
Researchers from Abl Bio Inc. recently presented preclinical data for the novel asymmetrical CLL1/CD3 bispecific antibody ABL-602, being developed for the treatment of acute myeloid leukemia (AML).
Sex differences at the cellular level could explain why men respond less well to glioblastoma (GBM) treatments, according to a study led by the Washington University School of Medicine in St. Louis (WUSTL). The researchers found that male and female GBM tumor cells had different metabolic needs. GBM cells from male surgical samples absorbed more glutamine and had different nutritional preferences for amino acids.
RSS
